

## **Eslicarbazepine acetate monotherapy in post-stroke epilepsy: A post hoc analysis from randomized double-blind multicenter clinical trial (BIA-2093-311)**

F. Sales<sup>1</sup>, Rui Loureiro<sup>2</sup>, L. Magalhães<sup>2</sup>, J. Moreira<sup>2</sup>, H. Fernandes<sup>2</sup>, H. Gama<sup>2</sup>

<sup>1</sup>*Epilepsy Unit and Department of Neurology, Centro Hospitalar e Universitário de Coimbra, Portugal*

<sup>2</sup>*Department of Research and Development, Bial Portela & Ca. S.A., Portugal*

**Objective:** To determine efficacy and tolerability of eslicarbazepine acetate (ESL) monotherapy compared to controlled-release carbamazepine (CBZ-CR) in post-stroke epilepsy (PSE) patients. **Methods:** BIA-2093-311 was a phase III double-blind, randomized, parallel-group study, which demonstrated non-inferiority of ESL vs CBZ-CR for seizure freedom (SF) rates (*Epilepsia*. 2018, 59(2):479-491). A *post hoc* analysis was conducted for PSE vs. non-PSE patients to compare efficacy and tolerability of ESL and CBZ-CR. **Results:** 52/813 (6.4%) were PSE and 761/813 (93.6%) were non-PSE patients. PSE patients were older and had higher mean age of epilepsy onset. In the PSE and non-PSE groups, no difference in demographics and epilepsy characteristics was observed between ESL and CBZ-CR treatment arms. There was no difference in SF between ESL and CBZ-CR in PSE patients (risk difference= 0.60%) and non-PSE patients (risk difference=-3.5%). In PSE patients, no significant difference in incidence of at least one related treatment emerging adverse events (TEAEs) was observed (ESL 34.8% vs. CBZ-CR 55.2%,  $p=0.17$ ); however, ESL group had significantly lower discontinuation due to at least one related TEAE (ESL 4.3% vs. CBZ-CR 31.0%,  $p=0.03$ ). In non-PSE patients, ESL group had lower incidence of at least one related TEAE (ESL 42.6% vs. CBZ-CR 51.2%,  $p=0.02$ ); but discontinuation due to at least one related TEAE was similar in both groups (ESL 12.4% vs. CBZ-CR 12.8%,  $p=0.96$ ). **Conclusion:** No difference was observed in seizure freedom between ESL and CBZ-CR in both PSE and non-PSE patients. In PSE patients, ESL was associated with fewer discontinuations due to TEAEs.